Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abide Therapeutics Inc.

http://abidetx.com

Latest From Abide Therapeutics Inc.

Earlier R&D Programs, Maturing Candidates Emerge From Bristol’s Pipeline

BMS is advancing a growing Phase I and II R&D pipeline, including a Factor XIa inhibitor with lower bleeding risk than current anticoagulants, as well as other internal and external research programs.

Strategy Cardiovascular

Teva’s Austedo Fails In Tourette’s Syndrome

Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.

Clinical Trials Companies

Lundbeck Set For 'Transformative' Eptinezumab Launch

The Danish drugmaker's four 'strategic brands' – Brintellix, Abilify Maintena, Northera and Rexulti – are selling well. Now the focus is firmly on breaking into the anti-CGRP market with eptinezumab.

Sales & Earnings Neurology

Lundbeck CEO: Alder Buy Will Boost Pipeline

Deborah Dunsire tells Scrip that buying Alder offers Lundbeck a blockbuster prevention treatment for severe migraine patients, and helps rebuild Danish group’s prospects.

Deals Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
UsernamePublicRestriction

Register